Patients with larger diameter tumors were more likely to receive whole brain radiotherapy and SRS in addition to Her-2 targeted therapy (odds ratio = 2.3per cm maximal tumor size, p = 0.03 on regression analysis). This evidence concerns the gene ERBB2 and neoplasm.